Ten years of anti-vascular endothelial growth factor therapy
Ten years of anti-vascular endothelial growth factor therapy
复制标题
DOI：
10.1038/nrd.2015.17
复制
发表时间：
2016-06-01
影响因子：
120.1
通讯作者：
Adamis, Anthony P.
中科院分区：
文献类型：
--
作者：
Ferrara, Napoleone;Adamis, Anthony P.
血管内皮生长因子A（VEGFA）是正常和病理性血管生成的关键调节因子，其靶向作用揭示了肿瘤学和眼科学的创新治疗方法。第一个VEGFA抑制剂贝伐单抗于2004年被美国食品和药物管理局批准用于转移性结直肠癌的一线治疗，第一个VEGFA抑制剂眼科pegaptanib和ranibizumab分别于2004年和2006年获得批准。为了纪念抗VEGFA治疗十周年，我们讨论了VEGFA的发现，VEGFA抑制剂开发的成功和挑战，以及这些药物对癌症和眼科疾病治疗的影响。
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic colorectal cancer, and the first VEGFA inhibitors in ophthalmology, pegaptanib and ranibizumab, were approved in 2004 and 2006, respectively. To mark this tenth anniversary of anti-VEGFA therapy, we discuss the discovery of VEGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases.